1-10 of 10
Domenico Coppola
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Available to Purchase
Ciara L. Freeman, Reginald Atkins, Indumathy Varadarajan, Meghan Menges, Jeffrey Edelman, Rachid Baz, Jason Brayer, Omar Castaneda Puglianini, Jose Leonel Ochoa-Bayona, Taiga Nishihori, Kenneth H. Shain, Bijal Shah, Dung Tsa Chen, Linda Kelley, Domenico Coppola, Melissa Alsina, Scott Antonia, Claudio Anasetti, Frederick L. Locke
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4575–4585.
https://doi.org/10.1158/1078-0432.CCR-22-3987
Published: 14 November 2023
View articletitled, Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Open the PDF for Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma in another window
Includes: Supplementary data
Journal Articles

Abstract A12: Cardiac hormone receptor A, NPRA, as a prognostic marker and target for prostate cancer therapy

Free
Xiaoqin Wang, Ronil Patel, Gary Hellerman, Domenico Coppola, Shyam S. Mohapatra, Subhra Mohapatra
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): A12.
https://doi.org/10.1158/1078-0432.TCMUSA10-A12
Published: 02 February 2016
View articletitled, Abstract A12: Cardiac hormone receptor A, NPRA, as a prognostic marker and target for prostate cancer therapy
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Free
Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View articletitled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Free
Beata Holkova, E. Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader, Neha Talreja, Martha D. Wellons, Kevin T. Hogan, G. David Roodman, Domenico Coppola, Loveleen Kang, Jana Dawson, Robert K. Stuart, Cody Peer, William D. Figg, Sr., Sarah Kolla, Austin Doyle, John Wright, Daniel M. Sullivan, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3388–3397.
https://doi.org/10.1158/1078-0432.CCR-10-2876
Published: 15 May 2011
View articletitled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice

Free
Maria E. Balasis, Kara D. Forinash, Y. Ann Chen, William J. Fulp, Domenico Coppola, Andrew D. Hamilton, Jin Q. Cheng, Saïd M. Sebti
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2852–2862.
https://doi.org/10.1158/1078-0432.CCR-10-2544
Published: 01 May 2011
View articletitled, Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice
Open the PDF for Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer

Free
Joseph A. Sparano, Stacy Moulder, Aslamuzzaman Kazi, Domenico Coppola, Abdissa Negassa, Linda Vahdat, Tianhong Li, Christine Pellegrino, Susan Fineberg, Pam Munster, Mokenge Malafa, David Lee, Shira Hoschander, Una Hopkins, Dawn Hershman, John J. Wright, Celina Kleer, Sofia Merajver, Said M. Sebti
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2942–2948.
https://doi.org/10.1158/1078-0432.CCR-08-2658
Published: 15 April 2009
View articletitled, Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer
Open the PDF for Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer in another window
Journal Articles

Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model

Free
Loree Heller, Kathleen Merkler, Jeffrey Westover, Yolmari Cruz, Domenico Coppola, Kaaron Benson, Adil Daud, Richard Heller
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3177–3183.
https://doi.org/10.1158/1078-0432.CCR-05-2727
Published: 17 May 2006
View articletitled, Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model
Open the PDF for Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model in another window
Journal Articles

Dedifferentiation Precedes Invasion in the Progression from Barrett's Metaplasia to Esophageal Adenocarcinoma

Free
James Helm, Steven A. Enkemann, Domenico Coppola, James S. Barthel, Scott T. Kelley, Timothy J. Yeatman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (7): 2478–2485.
https://doi.org/10.1158/1078-0432.CCR-04-1280
Published: 06 April 2005
View articletitled, Dedifferentiation Precedes Invasion in the Progression from Barrett's Metaplasia to Esophageal Adenocarcinoma
Open the PDF for Dedifferentiation Precedes Invasion in the Progression from Barrett's Metaplasia to Esophageal Adenocarcinoma in another window
Journal Articles

Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies

Free
Domenico Coppola, Marianna Szabo, David Boulware, Patrick Muraca, Marwan Alsarraj, Ann F. Chambers, Timothy J. Yeatman
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 184–190.
https://doi.org/10.1158/1078-0432.CCR-1405-2
Published: 20 January 2004
View articletitled, Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies
Open the PDF for Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies in another window
Journal Articles

Activation and Overexpression of Centrosome Kinase BTAK/Aurora-A in Human Ovarian Cancer

Free
Tatiana M. Gritsko, Domenico Coppola, June E. Paciga, Lin Yang, Mei Sun, Sue A. Shelley, James V. Fiorica, Santo V. Nicosia, Jin Q. Cheng
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1420–1426.
Published: 01 April 2003
View articletitled, Activation and Overexpression of Centrosome Kinase BTAK/Aurora-A in Human Ovarian Cancer
Open the PDF for Activation and Overexpression of Centrosome Kinase BTAK/Aurora-A in Human Ovarian Cancer in another window